Literature DB >> 3401271

[Pharmacokinetics and laxative effect of bisacodyl following administration of various dosage forms].

W Roth1, K Beschke.   

Abstract

Since its introduction into the market in 1952, bisacodyl has been successfully used worldwide as a laxative. In discussions on the kinetics and the laxative effect, it is often neglected that results obtained after the administration of the pure compound bisacodyl cannot be transferred to distinctive bisacodyl formulations. The aim of the present investigation is therefore to study the absorption and the plasma level profile and to correlate plasma level profile and laxative effect after the administration of various dosage forms. 12 healthy volunteers were administered with 10 mg bisacodyl as an experimental solution, with an acid resistant, commercially available Dulcolax Dragees (2 x 5 mg) and with a 10 mg Dulcolax suppository. Following glucuronidase cleavage, mean maximum plasma levels of 236.5 +/- 59.2 ng/ml of bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM) were reached after the administration of the solution 1.7 h post administration (p.a.), however, the laxative effect did not occur until 5.7 h +/- 0.7 h p.a. The dominant biological half-life of deconjugated BHPM, the diphenol of bisacodyl which circulated as BHPM-glucuronide, was about 16.5 +/- 4.2 h. The dragee yielded the desired low plasma levels which were between 7 and 47 ng/ml at 4-10 h p.a. In comparison to the solution only 16% were absorbed after the administration of the dragee. The laxative effect started 7.7 h +/- 1.7 h p.a. with no apparent relationship between effect and plasma level. The administration of the suppository resulted 20 +/- 10 min p.a. in a prompt laxative effect, although in 6 out 12 subjects, the plasma levels were below the detection limit.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401271

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

Review 1.  Treating constipation during pregnancy.

Authors:  Magan Trottier; Aida Erebara; Pina Bozzo
Journal:  Can Fam Physician       Date:  2012-08       Impact factor: 3.275

2.  [Pharmacological treatment of constipation].

Authors:  S Müller-Lissner
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

3.  Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers.

Authors:  N Manabe; F Cremonini; M Camilleri; W J Sandborn; D D Burton
Journal:  Aliment Pharmacol Ther       Date:  2009-08-12       Impact factor: 8.171

Review 4.  Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation.

Authors:  Maura Corsetti; Sabine Landes; Robert Lange
Journal:  Neurogastroenterol Motil       Date:  2021-03-09       Impact factor: 3.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.